Warning: fopen(/home/virtual/enm-kes/journal/upload/ip_log/ip_log_2024-04.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 88 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 89 Therapeutic Effects of Metformin and Rosiglitazone in Korean Women with Polycystic Ovary Syndrome.
Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > Endocrinol Metab > Volume 20(5); 2005 > Article
Original Article Therapeutic Effects of Metformin and Rosiglitazone in Korean Women with Polycystic Ovary Syndrome.
Jee Young Oh, Eun Kyung Byun, Hwi Ra Park, Young Ju Choi, Hyo Jung Kim, Hye Jin Lee, Young Sun Hong, Yeon Ah Sung, Hye Won Chung
Endocrinology and Metabolism 2005;20(5):467-475
DOI: https://doi.org/10.3803/jkes.2005.20.5.467
Published online: October 1, 2005
  • 1,919 Views
  • 21 Download
  • 1 Crossref
  • 0 Scopus
1Department of Internal Medicine, Ewha Womans University College of Medicine, Korea.
2Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Korea.
Full Article

Download PDF Download PDF

Abstract

BACKGROUND
Insulin resistance is a central feature of polycystic ovary syndrome (PCOS), and hyperinsulinemia contributes to anovulation, oligo or amenorrhea, hyperandrogenism and infertility in women with PCOS. The use of insulin sensitizers, such as metformin or thiazolidinedione, in PCOS is becoming increasingly accepted. The purpose of our study was to evaluate the therapeutic effects of metformin and rosiglitazone on the metabolic and reproductive derangement, and find parameters predicting their therapeutic efficacy in Korean PCOS women. METHODS: Sixty-two women with PCOS were recruited. The baseline characteristics, including BMI, glucose tolerance test, lipid profiles, sex hormones and hyperinsulinemic euglycemic clamp test, were assessed. After the administration of the insulin sensitizer (metformin 1.5g/day or rosiglitazone 4mg/day) for 3 months, the insulin sensitivity was reassessed. A drug response was defined as menstrual restoration or pregnancy. RESULTS: Of the 62 women with PCOS, 36 gained restored regular menstruation, and a further 5 conceived (a drug response rate of 66.7%). There were no significant clinical differences between responders and nonresponders. Twelve weeks after taking the drugs, the insulin sensitivity was significantly improved (M-value 4.7+/-0.2 vs. 5.5+/-0.4mg/kg/min, P<0.05), and the free testosterone levels(72.5+/-39.9 vs. 45.8 +/-3.8pmol/L, P<0.05) were significantly decreased, without significant weight reduction. CONCLUSION: Metformin and rosiglitazone restored menstruation in 66.1% of women with PCOS. Hyperandrogenemia and insulin sensitivity were significantly improved with the use of the two drugs. However, metabolic or hormonal markers for predicting the drug response could not be found.

Related articles
Endocrinol Metab : Endocrinology and Metabolism
© Korean Endocrine Society.